​

Funding Round

Series E - REGiMMUNE

Series E - REGiMMUNE

Investment Firm

Overview

REGiMMUNE is a biotechnology company producing immune-regulatory therapeutics for life-threatening diseases and debilitating disorders.

Announced Date

May 10, 2017

Funding Type

Series E

Highlights

Location

Asia

Social

Investor Lead

Japan Asia Investment

Japan Asia Investment

Japan Asia Investment is a debt and early_stage_venture and late_stage_venture and seed firm.

SMBC Venture Capital

SMBC Venture Capital

SMBC Venture Capital is a early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

8

Investor Name
Participant InvestorOita Venture Capital
Participant InvestorSMBC Venture Capital
Participant InvestorMitsubishi UFJ Capital
Participant InvestorJapan Asia Investment
Participant InvestorMiyako Capital

Round Details and Background

REGiMMUNE raised $5684918 on 2017-05-10 in Series E

REGiMMUNE is a biotechnology company producing immune-regulatory therapeutics for life-threatening diseases and debilitating disorders.

Company Funding History

9

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 14, 2014
Series D - REGiMMUNE
9-9.2M
Aug 15, 2006
Seed Round - REGiMMUNE
3-1.6M
Feb 21, 2007
Series A - REGiMMUNE
7-4.2M
Feb 01, 2008
Series B - REGiMMUNE
9-6.0M

Recent Activity

There is no recent news or activity for this profile.